Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hythiam has reported that the US Patent and Trademark Office has allowed US patent for treatment of alcohol dependencies, which contains claims using a composition of matter for reducing a person's desire to drink alcohol.
Subscribe to our email newsletter
The patent will serve to enhance protection of the intellectual property underlying the company’s Prometa treatment program. This patent, the second allowance in the US, represents the securing of the last of the initial patents in both Europe and the US.
Hythiam’s Prometa treatment program is designed for use by healthcare providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamine, as well as combinations of these drugs. The Prometa program includes nutritional supplements, FDA-approved oral and IV medications used off-label and separately administered in a unique dosing algorithm, as well as psychosocial or other recovery-oriented therapy chosen by the patient and his or her treatment provider.